Dave Kappos Speaks at SEP Study Group and Japan Patent Attorneys Association’s 2023 SEP Workshop
March 20, 2023
On March 15, 2023, Cravath partner David J. Kappos delivered the keynote address at the SEP Study Group and Japan Patent Attorneys Association’s 10th annual SEP Workshop in Tokyo, Japan. Dave’s keynote discussed the significance of standard essential patents and their role in innovation in the United States and other recent SEP developments.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
Related News & Insights
Deals & Cases
March 09, 2023
Airspan’s Sale of Mimosa to Radisys
On March 8, 2023, Airspan Networks Holdings (“Airspan”), a provider of software and hardware for 5G networks and a pioneer in end‑to‑end Open RAN solutions that provide interoperability with other vendors, announced the signing of definitive agreements for the sale of Mimosa Networks, Inc. (“Mimosa”) to Radisys Corporation (“Radisys”), a wholly owned subsidiary of Jio Platforms Limited, which is a subsidiary of Reliance Industries Limited, on a debt free, cash free basis. Cravath is representing Airspan in connection with the transaction.
Deals & Cases
February 17, 2023
WiseTech Global’s Acquisition of Blume Global
On February 17, 2023, WiseTech Global, developer of the leading logistics execution software CargoWise, announced its acquisition of Blume Global (“Blume”), provider of a leading solution facilitating intermodal rail in North America, for $414 million. Blume is being acquired from funds managed by Apollo, EQT and other minority shareholders. Cravath is representing WiseTech Global in connection with the transaction.
Deals & Cases
February 14, 2023
Disney’s Successful Proxy Contest With Trian Fund
On February 9, 2023, The Walt Disney Company (“Disney”) issued a statement in response to Nelson Peltz’s announcement that Trian Fund is no longer pursuing a proxy contest at Disney. Cravath represented Disney in connection with this matter.
Deals & Cases
February 06, 2023
RedHill’s Agreement with HealthCare Royalty to Extinguish its Debt Obligations in Exchange for Movantik®
On February 6, 2023, RedHill Biopharma Ltd. (“RedHill”), a specialty biopharmaceutical company, announced the extinguishment of all RedHill’s debt obligations (including all principal, interest, revenue interest, prepayment premiums and exit fees) under the Credit Agreement between RedHill’s U.S. subsidiary RedHill Biopharma Inc. and HealthCare Royalty (“HCR”) dated February 23, 2020 (as amended) in exchange for the transfer of its rights in Movantik® (naloxegol) to Movantik Acquisition Co., an affiliate of HCR. Cravath is representing RedHill in connection with the transaction.
